Century Therapeutics appoints Joseph Truitt to board; CNTY-813 IND on track for Q4 2026

Century Therapeutics, Inc.

Joseph Truitt appointed to board effective Sept 9, 2026; serves as Class I director, term to 2028 annual meeting.
Truitt is CEO of iECURE; receives initial option grant of 148,000 shares vesting over 36 months and $40,000 annual retainer.
CNTY-813 iPSC-derived islet replacement for T1D on track for IND submission in Q4 2026 after FDA pre-IND alignment.
CNTY-308 CD19-targeted CAR-iT therapy expected to enter clinic in 2026; both use Allo-Evasion 5.0 platform.
Truitt previously CEO of BioSpecifics and Achillion; also chairman of Larimar Therapeutics (LRMR).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.